KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Accumulated Expenses (2017 - 2020)

Aquestive Therapeutics has reported Other Accumulated Expenses over the past 4 years, most recently at $201000.0 for Q4 2020.

  • For Q4 2020, Other Accumulated Expenses fell 17.28% year-over-year to $201000.0; the TTM value through Dec 2020 reached $201000.0, down 17.28%, while the annual FY2020 figure was $201000.0, 17.28% down from the prior year.
  • Other Accumulated Expenses for Q4 2020 was $201000.0 at Aquestive Therapeutics, down from $284000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $284000.0 in Q3 2020 and troughed at $97000.0 in Q1 2020.
  • A 4-year average of $213916.7 and a median of $215000.0 in 2018 define the central range for Other Accumulated Expenses.
  • On a YoY basis, Other Accumulated Expenses climbed as much as 54.35% in 2020 and fell as far as 49.48% in 2020.
  • Year by year, Other Accumulated Expenses stood at $225000.0 in 2017, then fell by 8.0% to $207000.0 in 2018, then grew by 17.39% to $243000.0 in 2019, then decreased by 17.28% to $201000.0 in 2020.
  • Business Quant data shows Other Accumulated Expenses for AQST at $201000.0 in Q4 2020, $284000.0 in Q3 2020, and $223000.0 in Q2 2020.